Biocept to Hold Business Strategy Conference Call Today

Rhea-AI Summary

Biocept, Inc. (NASDAQ: BIOC) has announced a conference call scheduled for June 7, 2022, at 4:00 p.m. Eastern time. The call aims to discuss a re-focused business strategy and address questions from participants. Pre-registration is available, enabling callers to bypass live operators. Biocept specializes in molecular diagnostic assays for cancer treatment and monitoring, including its CNSide™ assay for detecting metastatic cancer in the central nervous system. The company also offers RT-PCR COVID-19 testing.

Positive

• Conference call indicates active management engagement with shareholders.
• Focus on strategic business rationalization could enhance operational efficiency.
• Expansion into COVID-19 testing reflects adaptability to public health needs.

Negative

• None.

SAN DIEGO--(BUSINESS WIRE)-- Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call today, June 7, 2022, beginning at 4:00 p.m. Eastern time to discuss its re-focused and rationalized business strategy and to answer questions.

Participants can pre-register for the conference call here. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

The conference call can be accessed at the time of the live call by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4109 for other international callers. A live webcast of the conference call will be available on the investor relations page of the Company’s website at http://ir.biocept.com/events.cfm.

A replay of the call will be available for 48 hours following its conclusion and can be accessed by dialing (877) 344-7529 for domestic callers, (855) 669-9658 for Canadian callers or (412) 317-0088 for other international callers. Please use event passcode 8040195. A replay of the webcast will be available for 90 days.

About Biocept

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide™ cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept’s patented Target Selector™ technology captures and quantitatively analyzes cerebrospinal fluid tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer RT-PCR COVID-19 testing to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005389/en/

Investor & Media Contact:

LHA Investor Relations

Jody Cain

Jcain@lhai.com, (310) 691-7100

Source: Biocept, Inc.

FAQ

What is the purpose of Biocept's conference call on June 7, 2022?

The conference call will discuss Biocept's re-focused business strategy and answer participant questions.

How can I participate in the Biocept conference call?

Participants can pre-register for immediate access or dial in directly using provided phone numbers.

What services does Biocept provide?

Biocept develops molecular diagnostic assays for cancer and offers RT-PCR COVID-19 testing.

What technology does Biocept use for cancer detection?

Biocept uses its patented Target Selector™ technology for analyzing tumor cells in cerebrospinal fluid.